Quote | Exscientia Limited (NASDAQ:EXAI)
Last: | $5.18 |
---|---|
Change Percent: | 0.0% |
Open: | $5.14 |
Close: | $5.18 |
High: | $5.21 |
Low: | $4.89 |
Volume: | 570,726 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | Exscientia Limited (NASDAQ:EXAI)
2024-07-18 15:02:42 ET More on Exscientia Exscientia: Too Much Pessimism Exscientia plc (EXAI) Q1 2024 Earnings Call Transcript Exscientia: Drug Discovery Platform Attracting Partners And Cash Exscientia to lay off up to 25% of employees; shares down 10% ...
Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to com...
Message Board Posts | Exscientia Limited (NASDAQ:EXAI)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $EXAI News Article - Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to B | whytestocks | investorshangout | 05/03/2023 6:20:50 PM |
whytestocks: $EXAI News Article - Data Presented at AACR 2023 Highlights Exscientia's Clinical and P | whytestocks | investorshangout | 04/19/2023 2:25:45 PM |
whytestocks: $EXAI News Article - Exscientia Announces Collaboration with Charit to Advance Developm | whytestocks | investorshangout | 03/07/2023 1:30:46 PM |
whytestocks: $EXAI News Article - Exscientia Announces First-in-Human Study for Bristol Myers Squibb | whytestocks | investorshangout | 02/02/2023 4:45:54 PM |
whytestocks: $EXAI News Article - Exscientia to Present at Upcoming Investor Conferences in November | whytestocks | investorshangout | 11/01/2022 12:50:54 PM |
News, Short Squeeze, Breakout and More Instantly...
Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to com...
— State-of-the-art platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia’s ability to deliver high quality drug candidates at faster speed and lower cost — Exscientia ...